Trial Profile
A double-blind, randomized, two-period, two treatment, fixed sequence, crossover (fed versus fasted) study to evaluate the effect of food on pharmacokinetics of CBD with robust ECG monitoring in Healthy Volunteers (HVs)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors Claritas Pharmaceuticals
- 25 Mar 2019 New source identified and integrated (Australian New Zealand Clinical Trials Registry)
- 05 Oct 2018 New trial record
- 20 Sep 2018 According to a Kalytera Therapeutics media release, data from the study will be required by the FDA for the treatment and prevention program of GVHD.